Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program

We describe the findings from 1704 chemonaïve patients with malignant pleural mesothelioma who received either pemetrexed plus cisplatin or pemetrexed plus carboplatin

Armando Santoro

2010

Scholarcy highlights

  • Published results from a randomized phase III study of pemetrexed plus cisplatin in patients with malignant pleural mesothelioma demonstrated a significant survival benefit and higher response rate compared with cisplatin
  • Pemetrexed was under review by regulatory agencies, an International Expanded Access Program provided more than 3000 mesothelioma patients with access to single-agent pemetrexed or pemetrexed in combination with cisplatin or carboplatin in 13 countries
  • The efficacy evaluable population consisted of 745 patients in the pemetrexed plus cisplatin group and 752 patients in the pemetrexed plus carboplatin group for whom physician-reported tumor response was available
  • The pemetrexed plus cisplatin group demonstrated a response rate of 26.3% compared with 21.7% for the pemetrexed plus carboplatin group, with similar 1-year survival rates and median time to progressive disease
  • The most common grade 3/4 hematologic toxicity was neutropenia in 23.9% of the pemetrexed plus cisplatin group and 36.1% of the pemetrexed plus carboplatin group
  • The 1-year survival rate was 60.5% for the pemetrexed plus cisplatin group and 62.8% for the pemetrexed plus carboplatin group
  • The present report focuses on the subset of 1704 chemonaïve patients who were able to tolerate combination chemotherapy with either pemetrexed plus cisplatin or pemetrexed plus carboplatin
  • Phase III, randomized trial using the same dose, pemetrexed yielded a response rate of 41.3% in combination with cisplatin and a prolonged survival time when compared with single-agent cisplatin

Need more features? Save interactive summary cards to your Scholarcy Library.